Integrated transcriptomic and proteomic validation identifies SLC35D3 as a tumor-selective surface antigen for colorectal and neuroendocrine carcinomas

mRNA-positive cancer cell lines but not in negative control. Taken together, these transcriptomic and proteomic findings establish SLC35D3 as a tumor-selective surface antigen broadly represented in aggressive malignancies yet virtually absent from critical normal tissues, highlighting it as a promising new candidate for next-generation ADCs, TCEs, and CAR-T therapies in colorectal and neuroendocrine carcinomas.